A Novel Selective Block of the Suprascapular Nerve

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Ligament InjuryFracture
Interventions
PROCEDURE

LSIB + SSNB

Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)

Trial Locations (1)

9038

University Hospital of North Norway, Tromsø

All Listed Sponsors
collaborator

University of Tromso

OTHER

lead

University Hospital of North Norway

OTHER

NCT02035774 - A Novel Selective Block of the Suprascapular Nerve | Biotech Hunter | Biotech Hunter